On October 26, 2021 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) ("Trillium" or the "Company") reported that its securityholders approved a statutory arrangement with PF Argentum ULC ("PF Argentum") a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) ("Pfizer") at the special meeting of Trillium securityholders (Press release, Trillium Therapeutics, OCT 26, 2021, View Source [SID1234592006]). Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The special resolution approving the arrangement was approved by: (i) 99.61% of the votes cast by Trillium shareholders voting as a single class present in person or represented by proxy and entitled to vote at the meeting; and (ii) 99.64% of the votes cast by Trillium shareholders and warrant holders, voting as a single class present in person or represented by proxy and entitled to vote at the meeting.

A non-binding resolution approving the compensation that may become payable to certain executive officers of Trillium in connection with the arrangement was also approved by 97.11% of the votes cast by holders of Trillium common shares present in person or represented by proxy at the meeting.

Upon closing of the arrangement, Trillium shareholders other than Pfizer and its affiliates will receive US$18.50 per share in cash subject to any applicable withholdings and other source deductions, and warrant holders will receive, at the holder’s election, (1) a cash payment equal to the amount by which US$18.50 exceeds the exercise price per share of such warrant, subject to applicable withholdings and other source deductions, or (2) a cash payment equal to the Black Scholes value of such warrant (as calculated pursuant to the terms and conditions of the certificate governing such warrant), subject to applicable withholdings and other source deductions.

The arrangement is subject to court and regulatory approvals and clearances, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in the fourth quarter of 2021 or the first half of 2022.

On October 26, 2021 FibroGen, Inc. (NASDAQ: FGEN) reported that it will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close (Press release, FibroGen, OCT 26, 2021, View Source [SID1234591937]). FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company’s corporate and financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the FibroGen website at View Source It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

A replay of the webcast and investor presentation will be available shortly after the call for a period of 7 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 1747879.

On October 26, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) reported that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares ("ADSs") representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission ("SEC") (Press release, Evotec, OCT 26, 2021, View Source;announcements/press-releases/p/evotec-se-announces-launch-of-public-offering-of-american-depositary-shares-6106 [SID1234591954]). Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs. The sale of the ADSs and the issuance of the underlying ordinary shares will be made under exclusion of shareholders pre-emptive rights based on Evotec’s existing authorized capital. Evotec has applied to list its ADSs on the Nasdaq Global Select Market under the symbol "EVO".

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The final price of the offered ADSs will be determined largely on the basis of the closing price of Evotec’s shares on the Frankfurt Stock Exchange on the pricing date (expected for the week of 1 November, 2021) translated into U.S. dollars at the then prevailing exchange rate and using an ADS to share ratio of 2 to 1.

BofA Securities and Morgan Stanley are acting as lead joint book-running managers for the offering. Citigroup, Jefferies, Cowen and RBC Capital Markets are acting as joint book-running managers for the offering.

Evotec intends to use the net proceeds from the offering to expand its biologics manufacturing capacity in the United States, build additional J.POD capacity in Toulouse, France, expand its precision medicine platform, accelerate pipeline activities, expand its portfolio of EVOequity investments and the remainder for general corporate purposes.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus, when available, may be obtained from BofA Securities, NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department or by email at [email protected]

or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.

On October 26, 2021 DURECT Corporation (Nasdaq: DRRX) reported that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021 (Press release, DURECT, OCT 26, 2021, https://investors.durect.com/news-releases/news-release-details/durect-corporation-announce-third-quarter-2021-financial-results [SID1234591972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 26, 2021 Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, reported that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent (Press release, Lucence Diagnostics, OCT 26, 2021, https://www.businesswire.com/news/home/20211026005411/en/Lucence-and-Yemaachi-Launch-the-AMBER-Study-to-Detect-and-Characterize-Genomic-Alterations-in-Breast-Cancer-in-Women-in-Africa-and-Expand-Liquid-Biopsy-Access [SID1234591988]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study– Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer, also known as the AMBER Study– is a prospective, observational trial exploring the utility of a cfDNA liquid biopsy assay to identify actionable genetic mutations in metastatic breast cancer patients in Ghana. Using Lucence’s LiquidHALLMARK assay, the study will examine actionable mutations in genes including PIK3CA, BRCA1, BRCA2, and ESR1 in treatment-naive metastatic breast cancer patients recruited from Cape Coast Teaching Hospital with the goal of identifying and evaluating the mutation profiles of cancers in Ghanaian women.

"Lack of access to next-generation sequencing technologies is a critical component of existing disparities in oncology. Through this collaboration, we will make progress toward diversifying research and expanding access to molecular diagnostics in a way that is scalable, affordable, and saves lives," said Yaw Bediako, PhD, Co-founder & CEO of Yemaachi.

Breast cancer is the most common cancer in women, responsible for almost a third of all cancers in Africa, and the leading cause of cancer-related mortality in Ghanaian women. Yet African populations have been largely excluded from oncology research and clinical trials to date. Although the continent accounts for 17% of the world’s population, only 2% of genomic study participants are of African descent compared to 78% of European ancestry. At the same time, clinical research in oncology has the potential to be high impact in this population due to a fast-growing, treatment-naive population, significant disease burden and the greatest human genetic diversity of any region worldwide.

"Both Lucence and Yemaachi care deeply about diversifying precision oncology globally, have a shared desire to see individuals with cancer treated earlier and better, and believe liquid biopsy is a disruptive force in cancer diagnostics that more patients and oncologists should have access to, regardless of their country of origin. We are excited to partner with Yemaachi on this important work," said Min-Han Tan, MBBS, PhD, Founding CEO of Lucence.